NASDAQ:GILD

GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030

– Gilead expands the ALL4LIVER Grant, Providing Grant Funding to Organizations inAfrica, South America, Asia and Oceania, Europe and North America –   – Themed 'Test. Link. Prioritize', the Grant Program will Target Projects Focusing on Viral Hepatitis Elimination by 2030 –  SINGAPORE, July 28, ...

2023-07-28 12:00 5045

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients

FOSTER CITY, Calif. and SHANGHAI, June 4, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results from the primary analysis of the Phase 3 TROPiCS-02 study of Trodelvy® (sacituzumab govitecan...

2022-06-04 20:30 5883

Gilead Sciences' Pulse Survey Highlights Majority of People Living with HIV, Individuals at Risk and HIV Care Prescribers in Asia Pacific Experience Disruptions in HIV Care During COVID-19 Pandemic

HONG KONG, Nov. 30, 2020 /PRNewswire/ -- Gilead Sciences, Inc. today announced findings from a pulse survey conducted to evaluate the impact of the COVID-19 pandemic on the access and delivery of care in HIV, which includes testing, treatment and prevention, inAsia Pacific. The survey revealed ...

2020-11-30 10:40 6016

Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program

HONG KONG, Nov. 16, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the recipients of its first Asia HIV Research Scholar Program ("Program"). The Program awards up toUS$130,000 over a period of two years to support innovative HIV scientific research led by early-career ...

2020-11-16 15:02 3649

Gilead Sciences Presents Findings from Clinical Studies Evaluating Patients Who Switched to Biktarvy(R) at 2020 Asia Pacific AIDS & Co-infections Conference

HONG KONG, Oct. 15, 2020 /PRNewswire/ -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced findings from multiple studies in Asian population that evaluated the safety and efficacy of switching to once-daily, single tablet regimen, Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir...

2020-10-15 14:10 7391

Week's Top Stories